CASP3 and adenoma of small intestine: Following 4 h exposure of Apcmin/+ mice to combined EGFR/IGF1R antagonism, there is a reduction in small intestinal adenoma mitotic scoring (0.4%±0.3 (combo) vs 2.1%±0.4 (gefitinib), P=0.04) and Brdu cell labelling (16.9%±4 (combo) vs 28.6%±1.4 (gefitinib), P=0.04) compared with gefitinib, without the detection of an increased level of small intestinal adenoma apoptosis (1.4%±0.5 (combo) vs 1.9±0.4 (gefitinib)) or caspase-3 scoring (5.2%±3.8 (combo) vs 10.1%±0.7 (gefitinib).